Table 1 Basic characteristics of the included diabetes RCTs published between 2000 and 2020
From: Twenty-year trends in racial and ethnic enrollment in large diabetes randomized controlled trials
Trial characteristics | Overall RCTs (n = 405) |
|---|---|
Year of publication: n (%) | |
 2000–2004 | 36 (8.9) |
 2005–2009 | 97 (24.0) |
 2010–2014 | 135 (33.3) |
 2015–2020 | 137 (33.8) |
Multi-country trials: n (%) | 327 (80.7) |
Sample size: median (Q1, Q3) | 716 (527, 1246) |
Age: median (Q1, Q3), years | 58 (55.0, 60.8) |
Female proportion: n (%) | 46 (39.9, 50.1) |
Trial aim: n (%) | |
 Glycemic control | 125 (30.9) |
 Management | 173 (42.7) |
 Complication | 105 (25.9) |
 Mixed | 2 (0.5) |
Trial reimbursement for patients: n (%) | 0 |
Outpatient enrolment: n (%) | 164 (40.4) |
Type of diabetes: n (%) | Â |
 Type 1 diabetes | 16 (4.0) |
 Type 2 diabetes | 346 (85.4) |
 Unspecified | 43 (10.6) |
Type of randomization: n (%) | |
 Individual | 399 (98.5) |
 Cluster | 6 (1.5) |
Type of intervention: n (%) | |
 Drug | 347 (85.7) |
 Lifestyle or education | 13 (3.2) |
 Device | 8 (2.0) |
 Others | 37 (9.1) |
Frequency of intervention: n (%) | |
 > 1 time/week | 325 (80.2) |
 1 ~ 4 times/month | 11 (2.7) |
 > 1 time/ year | 3 (0.7) |
 Not reported | 66 (16.4) |
Duration of intervention: median (Q1, Q3), months | 6.5 (6.0, 13.5) |
Type of follow-up: n (%) | |
 Face-to-face | 231 (57.0) |
 Telephone | 11 (2.7) |
 Others | 33 (8.1) |
 Not reported | 130 (32.2) |
Frequency of follow-up: n (%) | |
 Weekly | 6 (1.5) |
 Monthly | 32 (7.9) |
 Yearly | 29 (7.2) |
 Not reported | 338 (83.4) |
Duration of follow-up: median (Q1, Q3), months | 12 (6.0, 18.0) |
Funding source:Â n (%) | |
 Public | 67 (16.5) |
 Industry | 304 (75.0) |
 Combination | 28 (6.9) |
 Not reported | 6 (1.6) |